U.S.-based biotechnology company Black Diamond Therapeutics has raised $20 million in Series A funding.
With the funding from U.S.-based investment firm Versant Ventures, Black Diamond Therapeutics will strengthen its cancer research and development.
Black Diamond will use the money to establish operations in Toronto and support its drug programs.
Black Diamond expects the next financing in 2019 and push up to three programs into human testing within the next two years.